Private Limited Developments Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Private Limited Developments Pharmaceutical Import Records from India — 2 Products, $685.5K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Private Limited Developments — Pharmaceutical Importer Profile (2026) | 2 Products, $685.5K Trade | TransData Nexus

Private Limited Developments

Pharmaceutical Importer · United States · Antifungals Focus · $685.5K Total Trade · DGFT Verified

Private Limited Developments is a pharmaceutical importer based in United States with a total trade value of $685.5K across 2 products in 2 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Private Limited Developments sources from 4 verified Indian suppliers, with Encube Ethicals Private Limited accounting for 73.1% of imports.

Private Limited Developments — Import Portfolio & Supplier Network

Private Limited Developments import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Private Limited Developments?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Encube Ethicals Private Limited	$1.0M	34	73.1%
True Care Biomedix	$244.9K	7	17.1%
Vivimed Life Sciences Private Limited

What Formulations Does Private Limited Developments Import?

Formulation	Value	Ships
Miconazole nitrate 2 % vaginal cream usp1.59 oz / 45 GM with 7 applicator packwalgreens batch no. 3gp26a manufacturing . dt.	$170.7K	4
Miconazole nitrate 2 % vaginal cream usp1.59 oz / 45 GM with 7 applicator packwalgreens batch no. 3gp29 manufacturing . dt.	$72.7K	3
Miconazole nitrate 2 % vaginal cream usp1.59 oz / 45 GM with 7 applicator packequate batch no. 3gp25 manufacturing . dt.	$57.4K	2
Miconazole nitrate 2 % vaginal cream usp1.59 oz / 45 GM with 1 applicator packbatch no. 3gp30 manufacturing . dt. nov 2023	$52.9K	2
Clotrimazole 1 % cream 1 oz 28GM tubetpch batch no. 3gr03a manufacturing . dt. oct 2023 exp. dt. sep 2025 product code	$50.2K	2
Miconazole nitrate 2 % vaginal cream usp1.59 oz / 45 GM with 7 applicator packequate batch no. 3gp24 manufacturing . dt.	$50.0K	1
Acetaminophen & diphenhydraminehcl tablet 500/25MG other details as per document	$50.0K	1
Sennosides & docusate sodium tablet 8.6MG/50MG red other details as per inv&	$50.0K	1
Docosanol cream 10% 2g/0.07 oz pld batch no.3he06 manufacturing .date: oct 2023 exp.dt. sep	$50.0K	1
Abreva doco 10% cream 2GM ene 0.07 oz sub-asm batch no.3cx10 manufacturing .date: oct 2023 exp.dt. sep	$50.0K	1
Docosanol cream 10% 2g pld-wmt batchno.3he04 manufacturing .date: oct 2023 exp.dt. sep	$50.0K	1
Abreva doco 10% crm ene 0.07 oz sub-asmbatch no. 3cx11 manufacturing . dt. oct 2023 exp. dt. sep 2025 product code	$50.0K	1
Abreva doco 10% crm ene 0.07 oz sub-asmbatch no. 3cx11 manufacturing . dt. oct 2023 exp. dt. sep 2025 product code	$50.0K	1
Docosanol cream 10% 2gmpld-wmt- product code: sa001176 batch no. 3he05 manufacturing dt.oct 2023 exp dt. sep	$50.0K	1
Ibuprofen tablets USP 200 MG fcround- brown 1017 x 30000	$50.0K	1

Private Limited Developments imports 35 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Miconazole	Antifungals	$585.5K	20	3.0%	3
2	Docusate	Gastrointestinal	$100.0K	2	1.1%	10

Private Limited Developments imports 2 pharmaceutical products across 2 categories into United States totaling $685.5K.

Private Limited Developments — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Private Limited Developments is a United States-based pharmaceutical importer specializing in the procurement of finished pharmaceutical formulations from India. Operating as a private limited company, it plays a pivotal role in the U.S. pharmaceutical distribution network by sourcing and importing a diverse range of pharmaceutical products to meet domestic demand. The company's strategic focus on importing finished formulations underscores its commitment to delivering ready-to-use medications to the U.S. market.

Headquartered in the United States, Private Limited Developments maintains a robust presence in the pharmaceutical import sector. Its operations are characterized by a streamlined supply chain that emphasizes efficiency and compliance with U.S. regulatory standards. The company's role in the U.S. pharmaceutical distribution landscape is significant, as it bridges the gap between Indian pharmaceutical manufacturers and the U.S. healthcare system, ensuring the availability of essential medications to meet patient needs.

2Distribution Network

Private Limited Developments has established a comprehensive distribution network within the United States, encompassing strategically located warehouses and advanced logistics capabilities. This network ensures the efficient storage and distribution of imported pharmaceutical products across the country. The company's logistics infrastructure is designed to facilitate timely deliveries, maintaining the integrity and quality of the medications throughout the supply chain.

While the primary focus of Private Limited Developments is on the U.S. market, the company also explores opportunities for international distribution. By leveraging its established supply chain and logistics expertise, it aims to expand its reach beyond domestic borders, contributing to the global availability of quality pharmaceutical products.

3Industry Role

In the United States pharmaceutical supply chain, Private Limited Developments functions as a specialized importer of finished pharmaceutical formulations. By sourcing ready-to-use medications from Indian manufacturers, the company ensures a steady supply of essential drugs to the U.S. market. This role is crucial in meeting the diverse therapeutic needs of the population, particularly in areas where domestic production may be limited or insufficient.

The company's operations are characterized by a focus on compliance with U.S. regulatory standards, including those set by the Food and Drug Administration (FDA). By adhering to these standards, Private Limited Developments upholds the safety, efficacy, and quality of the pharmaceutical products it imports, thereby maintaining trust and reliability within the U.S. healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Private Limited Developments

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Private Limited Developments demonstrates a high degree of sourcing concentration, with 100% of its imported pharmaceutical products originating from India. This strategic focus on a single source country allows the company to leverage established relationships and streamline procurement processes. However, this concentration also introduces potential risks, such as exposure to geopolitical factors, regulatory changes, and supply chain disruptions within India.

The company's shipment data reveals a stable relationship with its Indian suppliers, characterized by consistent order volumes and a diversified product portfolio. This stability suggests a well-established and mutually beneficial partnership, which is essential for maintaining a reliable supply of pharmaceutical products. Nonetheless, the lack of alternative sourcing options may limit the company's flexibility in responding to unforeseen challenges in the supply chain.

2Supply Chain Resilience

The resilience of Private Limited Developments' Indian supply chain is influenced by several factors, including the regulatory compliance of its key suppliers and the diversity of formulations imported. The company's primary supplier, ENCUBE ETHICALS PRIVATE LIMITED, accounts for a significant portion of the imports, indicating a deep reliance on this supplier. While this relationship offers stability, it also poses risks if the supplier faces operational challenges or regulatory issues.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA's mission is to protect public health by ensuring that drugs imported into the U.S. meet the same standards for quality, safety, and effectiveness as those produced domestically. This includes rigorous evaluation of drug formulations, manufacturing processes, and labeling to ensure compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The FDA's regulatory framework for pharmaceutical imports is comprehensive, encompassing requirements for drug approval, manufacturing practices, and labeling. Imported drugs must be approved by the FDA, manufactured in compliance with Current Good Manufacturing Practices (CGMP), and labeled according to FDA regulations. This framework is designed to maintain the integrity of the U.S. drug supply chain and protect consumers from substandard or unsafe medications.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. Importers must ensure that all drugs comply with FDA regulations, including those pertaining to drug approval, manufacturing practices, and labeling. Drugs imported into the U.S. must be approved by the FDA, manufactured in compliance with Current Good Manufacturing Practices (CGMP), and labeled according to FDA regulations. This ensures that imported drugs meet the same standards for quality, safety, and effectiveness as those produced domestically.

Private Limited Developments — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Private Limited Developments' focus on importing finished pharmaceutical formulations in the antifungal and gastrointestinal therapeutic categories aligns with specific market demands in the United States. The prevalence of conditions such as fungal infections and gastrointestinal disorders necessitates a consistent supply of effective treatments. By concentrating on these areas, the company addresses critical healthcare needs and positions itself as a key supplier of essential medications.

The market demand for these products is driven by factors such as the aging population, increasing incidence of chronic diseases, and the need for cost-effective treatment options. By importing these formulations, Private Limited Developments contributes to the availability of affordable and effective medications, thereby supporting the overall health and well-being of the U.S. population.

2Sourcing Profile

Private Limited Developments employs a sourcing strategy that emphasizes the importation of generic drug formulations from India. This approach allows the company to offer cost-effective alternatives

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Private Limited Developments

What products does Private Limited Developments import from India?

Private Limited Developments imports 2 pharmaceutical products across 2 categories. Top imports: Miconazole ($585.5K), Docusate ($100.0K).

Who supplies pharmaceuticals to Private Limited Developments from India?

Private Limited Developments sources from 4 verified Indian suppliers. The primary supplier is Encube Ethicals Private Limited (73.1% of imports, $1.0M).

What is Private Limited Developments's total pharmaceutical import value?

Private Limited Developments's total pharmaceutical import value from India is $685.5K, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Private Limited Developments focus on?

Private Limited Developments imports across 2 categories. The largest: Antifungals (85.4%), Gastrointestinal (14.6%).

Get Full Private Limited Developments Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.